Provided by Tiger Trade Technology Pte. Ltd.

Dyne Therapeutics, Inc.

15.82
-0.2900-1.80%
Post-market: 15.820.00000.00%19:30 EDT
Volume:3.70M
Turnover:58.91M
Market Cap:2.95B
PE:-4.72
High:16.28
Open:16.01
Low:15.52
Close:16.11
52wk High:27.31
52wk Low:12.33
Shares:186.58M
Float Shares:186.00M
Volume Ratio:1.33
T/O Rate:1.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3486
EPS(LYR):-3.4740
ROE:-81.57%
ROA:-38.96%
PB:4.20
PE(LYR):-4.55

Loading ...

Dyne Therapeutics, Inc. : Raymond James Cuts Target Price to $37 from $40

THOMSON REUTERS
·
Sep 09

Dyne Therapeutics, Inc. : JP Morgan Cuts to Underweight from Neutral

THOMSON REUTERS
·
Sep 09

Dyne Therapeutics downgraded to Underweight from Neutral at JPMorgan

TIPRANKS
·
Sep 09

Small U.S. Stocks Close Lower; Dyne Therapeutics Posts Biggest Loss

Dow Jones
·
Sep 09

U.S. Stocks on the MOVE-Best Buy, Peloton, Apple

Reuters
·
Sep 09

Dyne Therapeutics falls -22.3%

TIPRANKS
·
Sep 08

Dyne Therapeutics Set for Biggest Single-Day Drop Since Jan 2025; Last Down 22%

THOMSON REUTERS
·
Sep 08

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Reuters
·
Sep 08

Sarepta Therapeutics Down 11.4%, Dyne Therapeutics Down 22%

THOMSON REUTERS
·
Sep 08

Top Premarket Decliners

MT Newswires Live
·
Sep 08

Dyne Therapeutics to Present One-Year Phase 1/2 Achieve Data for DM1 Drug DYNE-101 at Upcoming Meetings

Reuters
·
Sep 08

Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 Achieve Trial of Z-Basivarsen (Dyne-101) for Myotonic Dystrophy Type 1 (Dm1) at Upcoming Medical Meetings

THOMSON REUTERS
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN), NewAmsterdam Pharma Company (NAMS) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Sep 08

Sarepta, Dyne Sink After Novartis Muscle Disorder Trial Failure

Reuters
·
Sep 08

Sarepta Therapeutics Down 15.6%, Dyne Therapeutics Down 29%

THOMSON REUTERS
·
Sep 08

Shares of Some Drug Developers Fall Premarket After Novartis Late-Stage Muscle Disorder Trial Fails

THOMSON REUTERS
·
Sep 08

Novartis Twin Drug Setbacks Pile Pressure on Pipeline, CEO

Reuters
·
Sep 08

Dyne Therapeutics Advances Four DMD Exon-Skipping Candidates into IND-Enabling Studies

Reuters
·
Sep 03

Dyne Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Sep 02

Analysts’ Top Healthcare Picks: Dyne Therapeutics (DYN), Universal Health (UHS)

TIPRANKS
·
Aug 25